

ASX ANNOUNCEMENT

CELLMID'S ALOPECIA PATENT ALLOWED IN AUSTRALIA AND JAPAN

- **Australian and Japanese Patent Offices issue notices of allowance for patents protecting the Company's hair care technology**
- **Comprehensive protection over the use of certain monoterpenoids for treatment and prevention of hair loss**
- **Allowances add to previous patent grants for all évolis® formulations in China and Europe, extending international coverage**

SYDNEY, Friday, 24 April 2020: Cellmid Limited (ASX: CDY) is pleased to advise that IP Australia has issued a notice of allowance for the Australian Patent Application 2014361754 entitled "*Method of treatment of Alopecia with Monoterpenoids*" (Monoterpenoids Patent) and the Japanese Patent Office has also issued a notice of allowance for the same patent (Japanese Application No. 2016-539121).

The Monoterpenoids Patent for alopecia, owned by Cellmid's wholly owned subsidiary, Advangen Limited, protects a component of the technology that distinguishes the évolis® therapeutic and anti-aging hair care ranges from other products. The expiry date of the patent is 12 December 2034.

These patents provide protection in two key territories representing major markets for the Company's hair therapy formulations. The patents cover members of a class of small molecules called monoterpenoids, originally derived from botanical extracts. Granting of these patents in Australia and Japan is an important step for this patent family, extending coverage by previous grants in Europe and China (ASX Announcements, 2 April 2019 and 4 February 2020).

The method covered by the Monoterpenoids Patent involves administering a topical formulation containing a monoterpenoid to inhibit the hair growth cycle regulatory protein fibroblast growth factor 5 (FGF5). Detailed scientific studies¹ have shown that FGF5 activity in hair follicles is associated with disruption of the hair cycle, leading to withdrawal from the growth or anagen phase and entry into the regressive catagen phase, followed by follicle rest and hair loss.

Rigorous testing of various monoterpenoid compounds by the Advangen Hair Gene Research Laboratory in Tokyo, Japan, showed that several were potent inhibitors of FGF5, enabling hair follicles to maintain growth in the anagen phase. (Previous ASX announcement, 2 March 2017).

¹ For example: Higgins, *et al.* 2014. "FGF5 is a crucial regulator of hair length in humans" *PNAS*, 11(29):10648-53

Topical application of formulations containing key botanical extracts and FGF5-inhibiting monoterpenoids is central to Advangen's évolis® products against hair loss. The évolis® products containing monoterpenoid compounds have been shown to reduce hair loss and increase the number of actively growing follicles in a blinded, placebo controlled clinical study [published in the journal *Clinical, Cosmetic, and Investigational Dermatology* (2017) **10**: 71-85]. (Previous ASX announcement, 2 March 2017).

The imminent granting of these Australian and Japanese patents comes at a key time when emerging from the impact of the COVID-19 pandemic, and securing new distribution, will be assisted by a strong intellectual property position for the évolis® and évolis® Professional brands.

Approved by the Board of Directors of Cellmid Limited.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830

 @mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with a consumer health business and biotech assets in development. Advangen is Cellmid's wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated anti-aging products for hair, skin and body. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au. Cellmid's wholly owned subsidiary, Lynamid, develops innovative novel therapies and diagnostic tests for age related diseases including inflammatory and autoimmune conditions. Most recently the Company commenced sale of a point of care diagnostic tests for SARS-CoV-2.

Forward looking statements

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of marketing and sales activities and competition.